Physician profile
Ari Ezratty
NPI 1033197819
$20,294.62
in general payments reported to CMS, 2019-2025
37 companies · $3,121 in 2025
The $3,121 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,194 · 2020: $1,702 · 2021: $3,054 · 2022: $3,391 · 2023: $3,360 · 2024: $3,473 · 2025: $3,121.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,954.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,954.35 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $2,220.49 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $2,167.48 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,102.95 | 2019-2025 | Farxiga, Wainua |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,451.92 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $1,441.37 | 2019-2025 | Eliquis, Camzyos |
| Janssen Pharmaceuticals, INC | $1,366.86 | 2019-2024 | Xarelto |
| Pfizer INC. | $1,168.01 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $999.67 | 2021-2025 | Verquvo, Capvaxive |
| Esperion Therapeutics, INC. | $915.95 | 2020-2025 | Nexletol |
| Abbott Laboratories | $837.09 | 2019-2025 | Mitraclip, Aveir, Gallant |
| Sanofi-Aventis U.S. LLC | $694.95 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $666.62 | 2022-2025 | |
| Boston Scientific Corporation | $620.02 | 2019-2025 | Watchman Flx, Watchman Access System, Bodyguardian |
| Novo Nordisk INC | $522.95 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Chiesi USA, INC. | $334.53 | 2019-2025 | Cleviprex, Kengreal, Juxtapid |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lexicon Pharmaceuticals, INC. | $313.14 | 2023-2024 | Inpefa |
| Daiichi Sankyo INC. | $304.96 | 2023-2025 | Injectafer |
| Regeneron Healthcare Solutions, INC. | $269.25 | 2019-2024 | Evkeeza, Praluent |
| Cvrx, INC. | $257.75 | 2024-2025 | Barostim Neo System |
| Arbor Pharmaceuticals, INC. | $248.90 | 2019-2021 | |
| Kowa Pharmaceuticals America, INC. | $239.28 | 2019-2023 | Livalo |
| Althera Pharmaceuticals LLC | $223.37 | 2021-2022 | |
| Heartflow, INC. | $148.56 | 2023-2025 | Ffrct |
| Medtronic Vascular, INC. | $105.44 | 2020 | |
| Kiniksa Pharmaceuticals, LTD. | $101.43 | 2023 | Arcalyst |
| Inspire Medical Systems, INC. | $98.56 | 2023-2025 | Inspire |
| Lilly USA, LLC | $92.67 | 2025 | Zepbound |
| Kestra Medical Technology Services, INC. | $83.86 | 2022-2023 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $51.73 | 2024 | Arcalyst |
| Glaxosmithkline, LLC. | $45.80 | 2025 | Shingrix, Arexvy |
| Csl Behring | $45.30 | 2020 | |
| Alnylam Pharmaceuticals INC. | $36.05 | 2025 | Amvuttra |
| Lundbeck LLC | $33.76 | 2019 | |
| Baxter Healthcare | $27.25 | 2024 | Hillrom - Cardiac Ambulatory Monitor |
| Impulse Dynamics (USA) INC. | $24.42 | 2021 | |
| Vifor Pharma, INC. | $18.70 | 2019 | |
| Gilead Sciences, INC. | $13.58 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ari Ezratty listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.